Search

Your search keyword '"Charlie Fox"' showing total 13 results
Start Over Author "Charlie Fox" Topic internal medicine
13 results on '"Charlie Fox"'

1. Prognostic Impact of the Presence of Barrett’s Esophagus and Intestinal Metaplasia on Esophageal Adenocarcinoma Survival

Author

Christopher H. Lieu, Charlie Fox, Frank I. Scott, David A. Katzka, Chloe Friedman, Samuel Han, Sachin Wani, Ana Gleisner, Megan Marsh, Jeffrey B. Kaplan, Jennifer M. Kolb, and Martin D. McCarter

Subjects
medicine.medical_specialty, business.industry, Barrett's esophagus, Internal medicine, medicine, Esophageal adenocarcinoma, Intestinal metaplasia, medicine.disease, business, Gastroenterology, Article
Abstract

Background/Aims: Barrett’s esophagus (BE), defined by the presence of intestinal metaplasia (IM) on histology, is thought to be the only identifiable precursor lesion for esophageal adenocarcinoma (EAC). Recent studies have suggested the possibility of an alternate, non-IM associated EAC that is a more aggressive form of EAC with worse survival. Among EAC patients, we aimed to compare survival of patients with and without IM at the time of diagnosis. Methods: This was a retrospective cohort study of all patients with histologic confirmed EAC evaluated at a tertiary care center from 2013 to 2019. Cases were categorized according to the presence or absence of IM on histologic specimens (Group I—IM-EAC and Group II—non-IM-EAC). We compared demographic characteristics, clinical stage, therapy, and survival between the 2 groups using the Chi-square and ANOVA tests (for categorical and continuous variables, respectively). We used Cox proportional hazards regression to determine the association of IM with overall survival, adjusting for sex, age at diagnosis, tumor location, histologic grade, and clinical stage. Results: A total of 475 patients were included in this analysis (mean age 64.8 years [SD 10.8], 89% white) and 109 (23.0%) had no evidence of IM. Compared with IM-EAC (Group I), individuals in the non-IM-EAC group were younger ( P = .01) and had a greater proportion of patients diagnosed with advanced disease (49.5 vs 20.2% for stage 4, P Conclusions: EAC without the presence of IM on histology was associated with worse survival compared to those with IM. Future prospective studies with detailed molecular sequencing are required to clarify if 2 separate phenotypes of EAC exist (IM-EAC and non-IM-EAC). If confirmed, this may have significant implications for screening and management strategies.

Published
2021

2. Association between pre-admission acid suppressive medication exposure and severity of illness in patients hospitalized with COVID-19

Author

Teldon B. Alford, Millie Chau, Kulwinder S. Dua, Gail McNulty, Abdul Haseeb, Gulsum Anderson, Joy M. Hutchinson, Gabriela N. Kuftinec, Amar R. Deshpande, Vaishali Patel, Soumil Patwardhan, Melanie Mays, Sunil Amin, B. Joseph Elmunzer, Amy Hosmer, Andrew M. Aneese, Rosemary Nustas, Weijing Tang, Natalia H. Zbib, Liam Hilson, Benita K. Glamour, Molly Orosey, Amitabh Chak, Christopher J. DiMaio, Vladimir M. Kushnir, Mohamed Azab, Maria Ines Pinto-Sanchez, Bryan G. Sauer, Georgios I. Papachristou, Ji Zhu, Jordan Wood, Rajesh N. Keswani, Raman Muthusamy, Nancy L. Furey, Emad Qayed, Anish Patel, James Philip G. Esteban, Stephanie Mitchell, Judy A. Trieu, Jeong Yun Yang, Melissa Saul, Lujain Jaza, Rebekah E. Dixon, Mary K. West, Joseph F. LaComb, Fadi Odish, Swati Pawa, Luis F. Lara, Harsh K. Patel, Lauren Wakefield, Ali Zakaria, Rishi Pawa, Ambreen A. Merchant, Zachary L. Smith, Sachin Wani, Uchechi Okafor, Jason R. Taylor, Alexandria M. Lenyo, Nick Hajidiacos, Dhiraj Yadav, Ahmed I. Edhi, Cyrus R. Piraka, Field F. Willingham, Katherine A. Hanley, V. Mihajlo Gjeorgjievski, Olga C. Aroniadis, Anish A. Patel, Vikesh K. Singh, Nauzer Forbes, Collins O. Ordiah, Laura Mathews, Ashwinee Condon, Heiko Pohl, Vikram S. Kanagala, Eric D. Shah, William M. Tierney, Christopher Huang, Harminder Singh, Lilian Cruz, Darwin L. Conwell, Kelley Wood, Evan Mosier, Patrick S. Yachimski, Janak N. Shah, Eric F. Howard, Molly Caisse, Sheryl J. Korsnes, Emil Agarunov, Yueyang Zhang, Galina Diakova, Andrew Canakis, Bethany J. Wolf, Duyen T. Dang, Zahra Solati, Haley Nitchie, Rebecca L. Spitzer, Michael L. Volk, James M. Scheiman, Nicholas G. Brown, Richard S. Kwon, Amrita Sethi, John A. Damianos, Thomas Hollander, Olga Reykhart, Delia Calo, Zaid Imam, Robin B. Mendelsohn, E. Fogel, Don C. Rockey, Charlie Fox, Adrienne Lenhart, Selena Zhou, Ian Sloan, Laith H. Jamil, Akbar K. Waljee, M. I. Canto, Michael S. Bronze, Ayesha Kamal, Jennifer M. Kolb, Caroline G. McLeod, James Buxbaum, Casey L. Koza, Marc S. Piper, and Abhinav Tiwari

Subjects
Adult, Male, 2019-20 coronavirus outbreak, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), medicine.drug_class, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Proton-pump inhibitor, Severity of Illness Index, Article, Internal medicine, Severity of illness, medicine, Humans, In patient, Aged, Retrospective Studies, Hepatology, business.industry, SARS-CoV-2, Gastroenterology, COVID-19, Proton Pump Inhibitors, Odds ratio, Middle Aged, Hospitalization, Histamine H2 Antagonists, Female, business
Published
2020

3. Digestive Manifestations in Patients Hospitalized with COVID-19

Author

Rosemary Nustas, Vikesh K. Singh, Nauzer Forbes, Judy A. Trieu, Molly Caisse, Fadi Odish, James M. Scheiman, Rebecca L. Spitzer, Delia Calo, Casey L. Koza, Janak N. Shah, Mary K. West, Kelley Wood, Yueyang Zhang, Amy Hosmer, Rebekah E. Dixon, Galina Diakova, Jason R. Taylor, Heiko Pohl, Weijing Tang, Jordan Wood, Laith H. Jamil, Abdul Haseeb, Vaishali Patel, Abhinav Tiwari, Amitabh Chak, Field F. Willingham, Joy M. Hutchinson, Melanie Mays, Stephanie Mitchell, Jeong Yun Yang, William M. Tierney, Soumil Patwardhan, Maria Ines Pinto-Sanchez, Collins O. Ordiah, Zaid Imam, Georgios I. Papachristou, Rishi Pawa, Millie Chau, Amar R. Deshpande, Akbar K. Waljee, Caroline G. McLeod, Natalia H. Zbib, B. Joseph Elmunzer, James Buxbaum, Dhiraj Yadav, Rajesh N. Keswani, Ayesha Kamal, Melissa Saul, Sheryl Korsnes, Kulwinder S. Dua, Luis F. Lara, Haley Nitchie, Don C. Rockey, Charlie Fox, Harminder Singh, Jennifer M. Kolb, Zachary L. Smith, Katherine A. Hanley, Bryan G. Sauer, Michael S. Bronze, Lujain Jaza, Mohamed Azab, V. Mihajlo Gjeorgjievski, Teldon B. Alford, Olga C. Aroniadis, Joseph F. LaComb, Michael L. Volk, Zahra Solati, Nick Hajidiacos, Benita K. Glamour, Gabriela Kuftinec, Selena Zhou, Vikram Kanagala, Marcia I. Canto, Ian Sloan, Duyen T. Dang, Evan L. Fogel, Valerie Durkalski, Swati Pawa, Marc S. Piper, Patrick Yachimski, Amrita Sethi, Andrew Canakis, Christopher J. DiMaio, Anish A. Patel, Adrienne Lenhart, Laura Mathews, Darwin L. Conwell, Alexandria M. Lenyo, Ali Zakaria, Eric F. Howard, Nicholas G. Brown, Olga Reykhart, Sachin Wani, Eric D. Shah, Lilian Cruz, Molly Orosey, Nancy Furey, Cyrus Piraka, Evan Mosier, Robin B. Mendelsohn, Ashwinee Condon, Uchechi Okafor, Andrew M. Aneese, Sunil Amin, Emad Qayed, Anish Patel, Vladimir Kushnir, Harsh K. Patel, Gulsum Anderson, Ambreen A. Merchant, Thomas Hollander, James Philip G. Esteban, Ahmed I. Edhi, Lydia D. Foster, Christopher S. Huang, Ji Zhu, Raman Muthusamy, Liam Hilson, Richard S. Kwon, Emil Agarunov, Lauren Wakefield, John A. Damianos, and Gail McNulty

Subjects
Adult, Male, Abdominal pain, medicine.medical_specialty, Adolescent, Nausea, Gastrointestinal Diseases, medicine.medical_treatment, digestive manifestations, Article, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Interquartile range, Internal medicine, medicine, Humans, Aged, hepatic manifestations, Mechanical ventilation, Aged, 80 and over, Hepatology, business.industry, SARS-CoV-2, Confounding, Gastroenterology, COVID-19, Odds ratio, Middle Aged, Diarrhea, gastrointestinal symptoms, 030220 oncology & carcinogenesis, North America, Vomiting, 030211 gastroenterology & hepatology, Female, medicine.symptom, business
Abstract

Background & Aims The prevalence and significance of digestive manifestations in coronavirus disease 2019 (COVID-19) remain uncertain. We aimed to assess the prevalence, spectrum, severity, and significance of digestive manifestations in patients hospitalized with COVID-19. Methods Consecutive patients hospitalized with COVID-19 were identified across a geographically diverse alliance of medical centers in North America. Data pertaining to baseline characteristics, symptomatology, laboratory assessment, imaging, and endoscopic findings from the time of symptom onset until discharge or death were abstracted manually from electronic health records to characterize the prevalence, spectrum, and severity of digestive manifestations. Regression analyses were performed to evaluate the association between digestive manifestations and severe outcomes related to COVID-19. Results A total of 1992 patients across 36 centers met eligibility criteria and were included. Overall, 53% of patients experienced at least 1 gastrointestinal symptom at any time during their illness, most commonly diarrhea (34%), nausea (27%), vomiting (16%), and abdominal pain (11%). In 74% of cases, gastrointestinal symptoms were judged to be mild. In total, 35% of patients developed an abnormal alanine aminotransferase or total bilirubin level; these were increased to less than 5 times the upper limit of normal in 77% of cases. After adjusting for potential confounders, the presence of gastrointestinal symptoms at any time (odds ratio, 0.93; 95% CI, 0.76–1.15) or liver test abnormalities on admission (odds ratio, 1.31; 95% CI, 0.80–2.12) were not associated independently with mechanical ventilation or death. Conclusions Among patients hospitalized with COVID-19, gastrointestinal symptoms and liver test abnormalities were common, but the majority were mild and their presence was not associated with a more severe clinical course.

Published
2020

4. Digestive Manifestations in Patients Hospitalized with COVID-19

Author

Vikesh K. Singh, Ashwinee Condon, Rosemary Nustas, Judy A. Trieu, Robin B. Mendelsohn, Don C. Rockey, Joy M. Hutchinson, Nauzer Forbes, Lujain Jaza, Eric F. Howard, Christopher S. Huang, Sheryl J. Korsnes, Delia Calo, Gabriela Kuftinec, Rebecca L. Spitzer, Vikram Kanagala, Maria Ines Pinto-Sanchez, Georgios I. Papachristou, Mary K. West, Andrew M. Aneese, Janak N. Shah, Stephanie Mitchell, Jennifer M. Kolb, Benita K. Glamour, Selena Zhou, Luis F. Lara, Gail McNulty, Kulwinder S. Dua, Jordan Wood, Duyen T. Dang, Jason R. Taylor, Ayesha Kamal, William M. Tierney, Harminder Singh, Jeong Yun Yang, Liam Hilson, Cyrus R. Piraka, Sunil Amin, Rebekah E. Dixon, B. Joseph Elmunzer, Vladimir Kushnir, Teldon B. Alford, Millie Chau, Richard S. Kwon, Abdul Haseeb, Emil Agarunov, Lydia D. Foster, Evan L. Fogel, Caroline G. McLeod, Charlie Fox, Laith H. Jamil, Olga C. Aroniadis, Joseph F. LaComb, Emad Qayed, Eric D. Shah, Harsh K. Patel, Ambreen A. Merchant, Michael L. Volk, Ali Zakaria, Valerie Durkalski, Amrita Sethi, Adrienne Lenhart, Swati Pawa, Rishi Pawa, Amar R. Deshpande, Marc S. Piper, Alexandria M. Lenyo, Bryan G. Sauer, Zahra Solati, James M. Scheiman, Dhiraj Yadav, Andrew Canakis, Heiko Pohl, Zachary L. Smith, Vaishali Patel, and Katherine A. Hanley

Subjects
Mechanical ventilation, medicine.medical_specialty, Abdominal pain, business.industry, Nausea, medicine.medical_treatment, Confounding, Odds ratio, Confidence interval, Diarrhea, Internal medicine, medicine, Vomiting, medicine.symptom, business
Abstract

BackgroundThe prevalence and significance of digestive manifestations in COVID-19 remain uncertain.MethodsConsecutive patients hospitalized with COVID-19 were identified across a geographically diverse alliance of medical centers in North America. Data pertaining to baseline characteristics, symptomatology, laboratory assessment, imaging, and endoscopic findings from the time of symptom onset until discharge or death were manually abstracted from electronic health records to characterize the prevalence, spectrum, and severity of digestive manifestations. Regression analyses were performed to evaluate the association between digestive manifestations and severe outcomes related to COVID-19.ResultsA total of 1992 patients across 36 centers met eligibility criteria and were included. Overall, 53% of patients experienced at least one gastrointestinal symptom at any time during their illness, most commonly diarrhea (34%), nausea (27%), vomiting (16%), and abdominal pain (11%). In 74% of cases, gastrointestinal symptoms were judged to be mild. In total, 35% of patients developed an abnormal alanine aminotransferase or total bilirubin level; these were elevated to less than 5 times the upper limit of normal in 77% of cases. After adjusting for potential confounders, the presence of gastrointestinal symptoms at any time (odds ratio 0.93, 95% confidence interval 0.76-1.15) or liver test abnormalities on admission (odds ratio 1.31, 95% confidence interval 0.80-2.12) were not independently associated with mechanical ventilation or death.ConclusionsAmong patients hospitalized with COVID-19, gastrointestinal symptoms and liver test abnormalities were common but the majority were mild and their presence was not associated with a more severe clinical course

Published
2020

6. Sa1246 YOUNGER PATIENTS WITH ESOPHAGEAL ADENOCARCINOMA (EAC) PRESENT WITH MORE ADVANCED DISEASE BUT EXHIBIT IMPROVED SURVIVAL: AN OUTCOMES STUDY USING THE NATIONAL CANCER DATABASE

Author

Martin D. McCarter, Ana Gleisner, Michael B. Cook, Chloe Friedman, Gary W. Falk, Christopher H. Lieu, Samuel Han, Charlie Fox, Jennifer M. Kolb, Patrick Hosokawa, Caitlin C. Murphy, Ravy K. Vajravelu, Sachin Wani, Frank I. Scott, and David A. Katzka

Subjects
Oncology, medicine.medical_specialty, business.industry, Internal medicine, Gastroenterology, medicine, Advanced disease, Cancer, Esophageal adenocarcinoma, Improved survival, Radiology, Nuclear Medicine and imaging, medicine.disease, business
Published
2020

7. Early-Onset Esophageal Adenocarcinoma Presents With Advanced-Stage Disease But Has Improved Survival Compared With Older Individuals

Author

Jennifer M. Kolb, Samuel Han, Frank I. Scott, Caitlin C. Murphy, Patrick Hosokawa, Sachin Wani, Michael B. Cook, Charlie Fox, Chloe Friedman, Martin McCarter, Ravy Vajravelu, Christopher H. Lieu, Ana Gleisner, Gary W. Falk, and David A. Katzka

Subjects
Male, Oncology, medicine.medical_specialty, Esophageal Neoplasms, Kaplan-Meier Estimate, Disease, Adenocarcinoma, Rate ratio, Article, Cohort Studies, Internal medicine, Epidemiology, medicine, Surveillance, Epidemiology, and End Results, Humans, Age of Onset, Mortality, Aged, Neoplasm Staging, Hepatology, business.industry, Incidence, Incidence (epidemiology), Hazard ratio, Age Factors, Gastroenterology, Middle Aged, medicine.disease, United States, Middle age, Barrett's esophagus, Female, business, SEER Program
Published
2020

9. Mo1999 YOUNG PATIENTS WITH ESOPHAGEAL ADENOCARCINOMA PRESENT WITH ADVANCED STAGE DISEASE BUT HAVE SIMILAR SURVIVAL COMPARED TO OLDER INDIVIDUALS

Author

Frank I. Scott, Jennifer M. Kolb, Martin D. McCarter, Sachin Wani, Megan D. Marsh, Christopher H. Lieu, Chloe Friedman, Samuel Han, Charlie Fox, and Ana Gleisner

Subjects
medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Advanced stage, Gastroenterology, Esophageal adenocarcinoma, Medicine, Disease, business
Published
2020

10. 127 THE VOLUME-OUTCOME EFFECT CALLS FOR CENTRALIZATION OF CARE IN ESOPHAGEAL ADENOCARCINOMA (EAC): RESULTS FROM A LARGE NATIONAL CANCER REGISTRY

Author

Caitlin C. Murphy, Sachin Wani, Michael B. Cook, Gary W. Falk, Samuel Han, Martin D. McCarter, Charlie Fox, Jennifer M. Kolb, Frank I. Scott, David A. Katzka, Christopher H. Lieu, Ravy K. Vajravelu, Patrick Hosokawa, Chloe Friedman, and Ana Gleisner

Subjects
Oncology, medicine.medical_specialty, Hepatology, business.industry, Volume outcome, Internal medicine, Gastroenterology, medicine, Esophageal adenocarcinoma, business, Cancer registry
Published
2020

11. Mo1013 INCREASING INCIDENCE OF ESOPHAGEAL ADENOCARCINOMA OCCURS IN OLDER ADULTS AND CONTRASTS WITH THE RISE OF COLORECTAL CANCER IN THE YOUNG: A UNITED STATES POPULATION-BASED STUDY

Author

Chloe Friedman, Martin D. McCarter, Ravy K. Vajravelu, Frank I. Scott, Michael B. Cook, David A. Katzka, Caitlin C. Murphy, Samuel Han, Gary W. Falk, Jennifer M. Kolb, Ana Gleisner, Christopher H. Lieu, Charlie Fox, and Sachin Wani

Subjects
Oncology, Population based study, medicine.medical_specialty, Hepatology, business.industry, Colorectal cancer, Incidence (epidemiology), Internal medicine, Gastroenterology, medicine, Esophageal adenocarcinoma, business, medicine.disease
Published
2020

12. Tu1016 OCCURRENCE OF ESOPHAGEAL ADENOCARCINOMA IN THE YOUNG IS UNCOMMON AND PRESENTS WITH MORE ADVANCED STAGE YET IMPROVED SURVIVAL: A POPULATION-BASED STUDY

Author

Sachin Wani, Christopher H. Lieu, Michael B. Cook, Gary W. Falk, Ana Gleisner, Ravy K. Vajravelu, Charlie Fox, Frank I. Scott, David A. Katzka, Jennifer M. Kolb, Samuel Han, Caitlin C. Murphy, Martin D. McCarter, and Chloe Friedman

Subjects
Oncology, Population based study, medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Advanced stage, Gastroenterology, medicine, Esophageal adenocarcinoma, Improved survival, business
Published
2020

13. Modification of forearm resistance vessels by exercise training in young men

Author

James M. Rankin, Nigel T. Cable, Charlie Fox, Daniel J. Green, and Roger R. Taylor

Subjects
Adult, Male, Nitroprusside, medicine.medical_specialty, Physiology, Blood Pressure, Vasodilation, Stimulus (physiology), Nitric oxide, chemistry.chemical_compound, Forearm, Heart Rate, Physiology (medical), Internal medicine, Humans, Medicine, Exercise, Methacholine Chloride, business.industry, Control subjects, body regions, medicine.anatomical_structure, chemistry, Dilator, Vascular resistance, Cardiology, Physical therapy, Vascular Resistance, Sodium nitroprusside, business, Blood Flow Velocity, medicine.drug
Abstract

The aim of this study was to determine whether a 4-wk handgrip training program would elicit changes in endothelium-dependent and endothelium-independent vasodilatation in resistance vessels of the human forearm. Minimum vascular resistance after a 10-min ischemic stimulus, an index of peak vasodilator capacity, was also determined. Forearm blood flow response to the endothelium-dependent vasodilator methacholine chloride did not change over the 4-wk-intervention period either in the group undertaking training (n = 11) or in control subjects (n = 6). Similarly, the response to sodium nitroprusside was not influenced by the handgrip training program. Peak vasodilator capacity of the trained forearms significantly increased, whereas no change was evident in the untrained limbs. These results suggest that 4 wk of forearm exercise training enhances peak vasodilator capacity of the vasculature without influencing stimulated activity of the nitric oxide dilator system.

Published
1994

Catalog

Books, media, physical & digital resources
See catalog results